Orencia patent expiry?

Orencia (abatacept) – Patent status

Bottom line

• All of the core U.S. patents that protected Orencia have expired, the last of them in 2018.
• Because it is a biologic, no small‑molecule generic version can be made, but the expired patents mean that biosimilar manufacturers are free to develop and apply for approval of an abatacept‑based product in the U.S. (the first U.S.‑approved biosimilar, Abatacept‑bs, received FDA approval in 2023).

International context

What this means for patients and prescribers

1. Orencia® is off‑patent in the U.S. – no brand‑name exclusivity remains.
2. No generic small‑molecule equivalent can be sold because abatacept is a biologic.
3. Biosimilar options: As of 2024, several biosimilar abatacept candidates have received regulatory approval in various markets (e.g., Abatacept‑bs in the U.S., Abatacept‑biom in the EU). These offer potentially lower cost alternatives but still require a physician’s prescription and appropriate monitoring.

Key Take‑away
The Orencia patents have long since expired (last one in 2018 in the U.S.), but the drug remains a biologic, so only biosimilar competitors are possible. If you’re considering a different product, discuss the available abatacept biosimilars with your healthcare provider.